Home › NDC Lookup › Ingredients › First Aid Antibiotic › 70000-0093-01
🧴image loading
(from DailyMed)

Leader Poly Bacitracin FIRST AID ANTIBIOTIC 500 [USP'U]/g; 10000 [USP'U]/g Ointment — NDC 70000-0093-1 (Billing 70000-0093-01)

by Cardinal Health 110, Inc. · 1 TUBE in 1 CARTON / 14 g in 1 TUBE

This is a package of Leader Poly Bacitracin FIRST AID ANTIBIOTIC 500 [USP'U]/g; 10000 [USP'U]/g Ointment from Cardinal Health 110, Inc., marketed since Jun 2021 and currently FDA-listed; retail pharmacies pay about $0.1586 per g (NADAC). It is this product's only package size.

NDC 70000-0093-01
🏷️ FDA NDC (as labeled) 70000-0093-1 billing pads the package segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 70000-0093-1 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
70000 labeler · 0093 product · 1 package
Package marketed since
Jun 1, 2021
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 7000000931 1
Medicaid fills, this package
186 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70000-0093-1
Product NDC 70000-0093
11-digit billing NDC 70000009301
NCPDP billing unit GM — per gram (weight)
RxCUI 308512
UNII 89Y4M234ES, 19371312D4
Application # M004
SPL Set ID 442e11aa-7d14-44f9-bf14-446018f1de0d
Established class (EPC) Polymyxin-class Antibacterial
Physiologic effect Decreased Cell Wall Synthesis & Repair
Chemical class Polymyxins
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-06-01
Route TOPICAL
Dosage form OINTMENT
Substance BACITRACIN ZINC; POLYMYXIN B SULFATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90109802104200
GPI class Poly Bacitracin
GCN Seq No 018322
GCN 62427
HICL code 007495
Ingredient (HICL) Bacitracin Zinc/Polymyxin B
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5W
Therapeutic class — specific (HIC3) Topical Antibiotics
AHFS code 84:04.04.00
AHFS class Antibacterials (84:04)
FDB label name POLY BACITRACIN OINTMENT
FDB brand name Poly Bacitracin
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 018322
  • GCN: 62427
  • GPI-14 (Medi-Span): 90109802104200
  • HICL (First Databank): 007495
  • AHFS class code: 84:04.04.00
  • RxCUI (RxNorm): 308512
Why two NDCs? The FDA registers this code as 70000-0093-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70000-0093-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Other antibiotics for topical use class.

Drug family (ATC) Other antibiotics for topical use, Other antibacterials, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name POLY BACITRACIN OINTMENT Ingredient Bacitracin Zinc/Polymyxin B
🧪 What is this product?

Leader Poly Bacitracin is a topical ointment marketed as an over-the-counter first aid antibiotic under FDA's OTC monograph rules. It contains two active ingredients, bacitracin zinc and polymyxin B sulfate, which are antibacterial agents typically used in first aid products applied to minor cuts, scrapes, and wounds. The ointment is meant to be applied directly to the skin to help prevent infection in small injuries.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.159 $2.22 / 14 g
Medicaid paysCMS SDUD · 12 mo $0.6458 $9.04 / 14 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per g) — tap or hover for the price & month
May 2023 Jan 2026 Apr 2026 Jul 2026 $0.159 $0.145
▲ Up 9% over the last 9 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70000-0093-01 You're viewing this Main listing 1 TUBE in 1 CARTON / 14 g in 1 TUBE 2021-06-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Double Antibiotic 500 [USP'U]/g; 10000 [USP'U]/g 62011-0097-01 Strategic 1 tube $0.107 — Discontinued save 33%
sunmark double antibiotic 500 [USP'U]/g; 10000 [USP'U]/g 49348-0274-72 Strategic 1 tube $0.115 — Availability likely save 28%
Double Antibiotic 500 [USP'U]/g; 10000 [USP'U]/g 51672-2044-02 Sun 1 tube $0.115 — Availability likely save 28%
Double Antibiotic 500 [USP'U]/g; 10000 [USP'U]/g 70677-1212-01 STRATEGIC 1 tube $0.115 — Availability likely save 28%
Leader Poly Bacitracin 500 [USP'U]/g; 10000 [USP'U]/gthis 70000-0093-01 Cardinal 1 tube $0.159 — Availability likely —
Double Antibiotic 400 [USP'U]/g; 5000 [USP'U]/g 21922-0092-05 Encube 1 tube — — FDA listed —
Antibiotic 500 [iU]/g; 10000 [iU]/g 51316-0044-01 CVS 1 tube — — FDA listed —
DG Poly Antibiotic First Aid Antibiotic 500 U/g; 10000 U/g 55910-0342-24 Dollar 1 tube — — FDA listed —
Double Antibiotic 500 [USP'U]/g; 10000 [USP'U]/g 58980-0012-01 STRATUS 144 packets — — FDA listed —
doubleantibioticointment 10000 [USP'U]/g; 500 [USP'U]/g 69396-0029-30 Trifecta 1 tube — — FDA listed —
Family Wellness First Aid Antibiotic 10000 [USP'U]/g; 500 [USP'U]/g 69396-0037-04 Trifecta 1 tube — — FDA listed —
Polysporin First Aid Antibiotic 500 [USP'U]/g; 10000 [USP'U]/g 69968-0060-01 Kenvue 9 g — — FDA listed —
Simply Neosporin First Aid Antibiotic 500 [iU]/g; 10000 [iU]/g 69968-0612-01 Kenvue 1 tube — — FDA listed —
Leader Poly Bacitracin 500 [USP'U]/g; 10000 [USP'U]/g 70000-0694-01 Cardinal 1 tube — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2021
On the market since
Jun 2021
📍
2026
Currently FDA-listed
5 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCardinal Health 110, Inc.
FDA applicationM004 (OTC MONOGRAPH DRUG)
Labeler code70000
First marketedJun 2021
Product typeHuman Otc Drug
Portfolio7 products on file

More NDCs from Cardinal Health 110, Inc. labeler code 70000

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor Before Use If 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 12 words ▾

Uses First aid to help prevent infection in minor: cuts scrapes burns

⏱️ Dosage and Administration 32 words ▾

Directions clean the affected area apply a small amount (equal to surface area of tip of finger) on the area 1 to 3 times daily. may be covered with a sterile bandage

⚠️ Warnings 115 words ▾

Warnings For external use only Allergy alert: do not use if you are allergic to any of the ingredients Do not use in or near the eyes on large areas of the body Consult a doctor before use if you have deep or puncture wounds animal bites serious burns When using this product do not use longer than 1 week Stop use and consult a doctor if condition persists or gets worse symptoms last for more than 7 days or clear up and come back within a few days a rash or other allergic reaction develops Keep out of the reach of children.

If swallowed get medical help or contact a Poison Control Center immediately.

🧪 Active Ingredient 13 words ▾

Active ingredients (In each gram) Bacitracin 500 units Polymyxin B Sulfate 10,000 units

🧪 Inactive Ingredients 3 words ▾

Inactive ingredient Petrolatum

🎯 Purpose 4 words ▾

Purpose First aid antibiotic

📄 Do Not Use 14 words ▾

Do not use in or near the eyes on large areas of the body

📄 Ask a Doctor Before Use If 16 words ▾

Consult a doctor before use if you have deep or puncture wounds animal bites serious burns

📄 When Using This Product 11 words ▾

When using this product do not use longer than 1 week

📄 Stop Use and Ask a Doctor If 36 words ▾

Stop use and consult a doctor if condition persists or gets worse symptoms last for more than 7 days or clear up and come back within a few days a rash or other allergic reaction develops

📄 Keep Out of Reach of Children 19 words ▾

Keep out of the reach of children. If swallowed get medical help or contact a Poison Control Center immediately.

📄 Questions or Comments 3 words ▾

Questions? Call; 1-800-222-1087

📄 Package Label / Principal Display Panel 80 words ▾

Principal Display Panel – Carton Label Leader Major NDC 70000-0093-1 Poly Bacitracin Zinc Ointment USP Bacitracin Zinc 500 units Polymixin B sulfate 10,000 units First Aid Antibiotic Ointment NET WT. 0.5 oz (14g) Principal Display Panel – Carton Label

Principal Display Panel – Tube Label Leader NDC 70000-0093-1 Poly Bacitracin Zinc Ointment Bacitracin Zinc 500 Units Polymixin B Sulfate 10,000 units First Aid Antibiotic Ointment Protection against Infection NET WT. 0.5 oz ( 14g) Principal Display Panel – Tube Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
186
Units reimbursed last 4 qtrs
4.1K
Gross reimbursed last 4 qtrs
$2.6K
Avg / prescription
$14.15
Avg / unit
$0.6459
Latest quarter Q4 2025
76Rx
Medicaid pays / g
$0.6459
gross reimbursed
vs
NADAC / g
$0.1586
acquisition cost
=
Spread
+$0.4873
+307% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
87% FFS 13% MCO
Fee-for-service · 162 Rx Managed care · 24 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: 450 units · 4.8 per 100k residents NJ Massachusetts: no data reported MA California: 3,625 units · 9.3 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
4.89.3
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 California 9.3 /100k
2 New Jersey 4.8 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for FIRST AID ANTIBIOTIC — the ingredient across all brands.

Top reported reactions

Drug Hypersensitivity33
Dyspnoea13
Fatigue13
Nausea13
Rash13
Pain12
Constipation11

Age at onset

Child3
Adolescent1
Adult18
Elderly9

Reporter sex

233 reports
Male · 44%
Female · 56%
Unknown · 0%

Serious outcomes

Hospitalization76
Life-threatening10
Reports over time (by year) — tap or hover for the count & year
2022 2023 2024 2026 14 4
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 70000-0092-01 · CARDINAL 70000-0094-01 · Cardinal →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.